Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CYP-006TK
- Development stage
- Unknown
- Lead developer
- Cynata Therapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Topical
01
Overview
CYP-006TK is an investigational combination product comprising allogeneic induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs), known as Cymerus™ MSCs, seeded onto a proprietary heptylamine plasma polymer-coated silicone wound dressing. Developed by Cynata Therapeutics in collaboration with TekCyte, the product is designed to treat chronic wounds, specifically diabetic foot ulcers (DFU). The Cymerus technology utilizes mesenchymoangioblasts (MCAs) as a precursor to produce a consistent and scalable supply of MSCs, avoiding the limitations of donor-derived bone marrow MSCs. The active dressing facilitates the localized delivery of these cells to the ulcer site, where they are intended to promote tissue repair and regeneration through paracrine signaling and the modulation of the wound microenvironment.
- Other names
- Cymerus MSC wound dressingCymerus MSCs seeded onto a heptylamine plasma polymer-coated silicone dressing
Beyond the preview
Go deeper on CYP-006TK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYP-006TK.